Since its low mRNA expression levels are reasonably offset by elevated protein expression and enzymatic activity as compared to other HAS [45] and since it exerts a significant role in cancer progression enriching the tumor microenvironment with pro-inflammatory and pro-tumorigenic HA fragments, HAS3 could be considered a future potential target in therapeutic MPM intervention. This evidence concerns the gene HAS3 and neoplasm.